Mineralys Therapeutics announced on September 25, 2024, that it has completed target enrollment for its pivotal Advance-HTN trial. This trial is evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.
The trial enrolled 261 subjects, who received lorundrostat as an add-on therapy to a standardized background treatment of two or three antihypertensive medications. This milestone keeps the company on track to announce topline data in the first quarter of 2025.
Achieving target enrollment is a critical step in the clinical development process, signaling progress towards potential regulatory submission. The company expressed optimism regarding lorundrostat's promise for hypertension treatment, building on observations from previous trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.